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Introduction
Gastrointestinal stromal tumors (GISTs) are neoplasms 
derived from the pacemaker cells of the gut-termed cells 
of Cajal. As a result, they can develop anywhere along the 
gastrointestinal (GI) tract, and they are the most common 
sarcoma and mesenchymal neoplasm of the GI tract. 
The management of advanced GIST has evolved in the 
modern era due to the discovery of c-kit mutations and the 
development of tyrosine kinase inhibitors (TKIs). Until 
the advent of TKIs such as imatinib, the median survival 
reported for patients with advanced GIST was 19 months 
(1,2). Although surgery is the treatment of choice for 
resectable primary GIST, its role in cases of recurrence and 
metastasis remains to be unclear. 
The following is a review of the literature for the role 
of surgical resection in the multidisciplinary treatment of 
advanced GIST in the era of TKIs.
Pre-TKI Era
Prior to the development of TKIs, surgical resection 
was the primary treatment for localized GIST. However, 
even in patients with resectable disease, the prognosis 
was unfavorable, as 5-year survival was only 54% (1,3). 
Furthermore, between 40% and 70% would develop 
recurrent or metastatic disease, with the median time 
from resection to recurrence being 2.4 years. Recurrence 
overwhelmingly occurs in the peritoneum, the liver, or 
both (3). Resection for recurrent disease was associated 
with a median survival of 15 months (4). While multiple 
chemotherapy agents had been trialed, none had any 
significant effect, as response rates were <10% (5). Resection 
of recurrent disease had mixed results. Resection of liver 
only recurrence was associated with 1- and 3-year survivals 
of 90% and 58%, respectively (6). Resection of metastatic 
disease resulted in a modest survival improvement with 
median survival being 27 months (1). 
Post-TKI era
Prognosis for patients diagnosed with GIST changed 
radically in 2002 with the approval of imatinib meslyate 
by the FDA as a treatment option. The landmark study by 
Demetri et al. showed the efficacy of imatinib to produce a 
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sustained objective response for unresectable and metastatic 
GIST translating to 24-month progression free survival 
(PFS) and 57-month overall survival (OS) (7). These results 
were confirmed by the B2222 trial. These two studies 
have established TKI therapy as the first line treatment of 
unresectable and metastatic GIST. 
Cytoreduction surgery following a positive response to 
TKI therapy was then shown to further improve survival. 
Fiore et al. demonstrated neoadjuvant TKI therapy to result 
in a 34% reduction in tumor size and 77% 3-year PFS in 
patients with unresectable or metastatic GIST (8). In another 
study performed by Blesius et al., 60% of patients with locally 
advanced GIST had a positive response to TKI therapy and 
those patients who then underwent resection had improved 
PFS and OS compared to those who continued with only 
TKI therapy (9). The PFS and OS benefits of cytoreductive 
surgery after a positive response to TKIs have been 
demonstrated in multiple additional studies (10-13). 
Two studies have specifically looked at the role for 
cytoreductive surgery of metastatic or recurrent GIST prior 
to TKI therapy. In a retrospective study of 249 patients 
by An et al., there was no improvement of PFS when 
comparing cytoreductive surgery followed by TKI vs. TKI 
alone (13). Change et al. observed an improvement in 1-, 
3-, and 5-year PFS in patients undergoing cytoreductive 
surgery followed by TKI therapy compared to TKI therapy 
alone; however, this did not translate into any significant 
improvement in OS (14).
Intolerance of TKI therapy
While TKIs are generally well tolerated, they are not 
without potential adverse effects. Most adverse effects are 
non-life threatening: nausea, vomiting, diarrhea, muscle 
cramps, fatigue, hypothyroidism and fluid retention can 
be typically managed with ancillary treatment. However, 
while serious adverse effects, such as leukopenia and 
cardiotoxicity, can often be managed, occasionally they are 
severe enough to require dose reductions or cessation of 
treatment (15-17). 
Development of TKI resistance
GIST resistance to TKIs develops in two patterns: primary 
and secondary. Primary resistance is defined as evidence of 
progression during the first 6 months of TKI therapy and 
is primarily seen in patients with wild-type GISTs that lack 
the KIT or PDGFR mutations. Secondary resistance is seen 
in patients who have been on TKI therapy for 6 months 
with an initial response or disease stabilization, which is 
then followed by progression. This resistance pattern is due 
to the outgrowth of tumor clones with secondary mutations 
in KIT (18-21). 
As far as time on therapy before surgery, the NCCN 
quotes the EORTC trial, which demonstrated a median 
time to secondary resistance of 2 years. They recommend 
discussing surgery around 6–12 months of disease stability 
or response. Finally, NCCN recommends continuation 
of imatinib therapy post-operatively based on a study by 
Rutkowski et al. that showed recurrent disease in patients 
who did not restart therapy. 
Indications
There are several retrospective studies examining the role 
for surgical resection after imatinib therapy (13,22-28); 
these revealed a higher complete resection rate and 
improved PFS and OS after surgery in patients who 
responded to TKI therapy versus those who were resistant. 
One of the most recent and largest studies by Fairweather 
et al. reported a 14-year experience [2001–2014] from 2 
institutions that identified radiographic response to TKI 
at time of surgery significantly influenced PFS. A similar 
outcome for the influence of radiographic response at time 
of surgery was observed in median OS from date of surgical 
resection (stable disease 110 months, unifocal progressive 
disease 59 months, and multifocal progressive disease 
26 months, P<0.001). Additionally, metastatic mitotic index 
≥5/50 HPF, presence of multifocal progressive disease, and 
R2 resection were all associated with worse PFS and OS. 
Two randomized controlled trials have been designed 
examined cytoreductive surgery in combination with 
imatinib (neoadjuvant therapy + surgery + adjuvant 
therapy with imatinib) vs. imatinib alone. The surgery arm 
outperformed imatinib alone in 1- and 3-year OS (100% vs. 
89% and 85% vs. 60%, respectively, P=0.03) (29). Of note, 
this trial had a small sample size. The second randomized 
controlled trial conducted by Du et al. examined if 
cytoreductive surgery for imatinib responsive recurrent 
or metastatic GIST was superior to imatinib treatment 
alone. Unfortunately, this trial was closed early due to poor 
accrual, and there was no statistically significant difference 
in 2-year PFS between the surgery arm and imatinib only 
arm (88.4% vs. 57.7%, P=0.089) (30).
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Prediction of effective surgery
Several studies have showed tumor responsiveness to 
imatinib before surgery to be associated with improved OS 
or PFS (13,22-24,26,31). Further studies have demonstrated 
surgery to have limited benefit in patients with focal 
progressive disease (22,26), while some show improved 
outcomes of patients with focally progressive GISTs 
resistant to TKI (32,33). 
A recent meta-analysis of nine studies included a total 
of 1,416 GIST patients, 351 received surgery. This analysis 
demonstrated that improved outcomes were associated 
with surgery and TKI in combination vs. TKI treatment 
alone in terms of OS (HR by random-effects model =0.68; 
95% CI, 0.54–0.85; I2=48.9%) and PFS (HR =0.50; 95% 
CI, 0.33–0.76; P<0.05; I2=17.9%; P=0.296) with metastatic 
or recurrent GISTs. The same report, conducted a sub-
analysis on OS among the two randomized controlled trials 
previously mentioned; however, there was no significant 
difference in OS among the RCT group. 
To specifically look at liver metastasis, being the most 
common site of metastasis, Brudvik et al. (34) compared 
survival data in patients with GIST vs. leiomyosarcomas 
and other sarcomas. They found a 5-year recurrence free 
survival rate of 35.7% for GIST (49 total GIST patients) 
with a median time to recurrence of 17.8 months. The liver 
was found to be the most common area of recurrence with 
a rate of 41% amongst those with recurrences. Importantly, 
their subgroup analysis showed GIST patients had a higher 
recurrence free survival rate at 5 years with imatinib vs. 
those who had surgical resection alone (47.1% vs. 9.5%; 
P=0.013). 
As for OS in their study, the 10-year OS was 52.5%. 
In a subgroup analysis they found that after resection of 
liver metastases from GIST, age greater than 55 years 
(HR =2.798; P=0.027) was associated with reduced OS, 
male sex (HR =0.447; P=0.071) exhibited a trend towards 
increased OS, and concomitant RFA (HR =2.179; P=0.085) 
and R1 resection (HR =4.100; P=0.066) exhibited trends 
toward reduced OS 
What requires further exploration is the question: who 
are the best candidates for surgical resection in metastatic 
and recurrent disease? One study performed by Roland 
et al. (35) looked to describe pre-operative characteristics 
that would predict favorable outcomes with surgical 
resection after imatinib therapy. They looked at 87 patients 
with metastatic or recurrent GIST who underwent 
preoperative TKI therapy as well as surgical resection. 
The median duration of neoadjuvant TKI therapy was 
667 days and 91% of patients continued TKI therapy 
post-operatively. At a median follow-up of 51 months 
from surgical resection for recurrent or metastatic GIST 
(91 months for survivors), the median OS was 64.5 months 
(95% CI, 39.2–90.9) with a median time to recurrence of 
21.3 months (95% CI, 12.7–29.2). Median disease-specific 
survival (DSS) was 73.5 months (95% CI, 39.9–97.7) from 
surgical resection. Median DSS from the time of initiation 
of TKI therapy was 119 months (95% CI, 72.2–142.4). 
In univariate analysis for pre-operative risk factors they 
found that unifocal disease at time of resection, duration 
of TKI therapy less than 365 days, and no evidence of 
radiographic progression were associated with improved 
time to recurrence and DSS. Additionally, on multivariate 
analysis, patients with evidence of radiographic tumor 
progression prior to surgical resection had a significantly 
worse GIST-specific survival (HR =2.53; 95% CI, 1.27–
5.06; P=0.008) and increased risk of recurrence (HR =3.33; 
95% CI, 1.91–5.82; P<0.001) compared to those with 
preoperative radiographic stable disease or regression. 
Patients with multifocal disease in single or multiple cavities 
also decreased GIST-specific survival (HR =2.61; 95% CI, 
1.12–6.06; P=0.027) compared to patients with unifocal 
disease.
In patients whose disease has been stable on TKI therapy 
who develop isolated progression due to TKI-resistent 
clones, targeted resection may improve survival by reverting 
the metastatic GIST patient to a TKI-induced indolent 
state (13). Thus, surveillance with a history and physical 
exam and CT or MRI should be performed to identify those 
who may benefit from further resection (36). 
Conclusions
Surgery for metastatic GIST should generally be performed 
after 6–12 months of TKI therapy, prior to development of 
secondary resistence, or sooner in the case of progressive 
disease. Cyto-reductive therapy improves PFS and OS 
relative to TKI therapy alone, especially in patients with 
advantageous biology. After resection, TKI therapy should 
be continued indefinitely. Initially, surveillance with 
history and physical exams as well as CT or MRI should be 
performed every 3–6 months. Further surgery for resectable 
disease or isolated progression can be pursued to remove 
TKI-resistent clones and revert the GIST to a TKI-induced 
indolent state.
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